diffuse large B-cell lymphoma
Conditions
Interventions
study group:Obinutuzumab 1000mg C1D1
Glotifamab 2.5mg C1D8
Glotifamab 10mg C1D15
Glotifamab 30mg D1(since Cycle2)
T
Sponsors
The first affiliated hospital Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) According to the fifth edition of WHO Classification of lymphohematopoietic tumors, the patient was pathologically diagnosed as diffuse large B-cell lymphoma; 2) Age =18; 3) The patient has disease progression or recurrence after at least 2 lines of therapy and has received at least one anti-lymphoma regimen containing CD20; 4) PET-CT or CT/MRI shows at least one two-dimensional measurable lesion (maximum diameter > 1.5cm); 5) Women of childbearing age must be confirmed not to be pregnant through pregnancy tests, and are willing to take effective contraceptive measures during the test period and =12 months after the last dose of medication; Pregnant and lactating women cannot participate; All male subjects used contraception during the study period and =3 months after the last dose; 6) Can provide informed consent, can understand and comply with the study requirements.
Exclusion criteria
Exclusion criteria: 1) Patients with severe mental illness; 2) HIV infection; 3) prior CD20×CD3 dual antibody therapy; 4) prior organ transplantation or allogeneic stem cell transplantation; 5) other active tumors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Progression-free survival;overall survival;safety; | — |
Countries
China
Contacts
Public ContactHongyan Tong
The first affiliated hospital Zhejiang University school of medicine
Outcome results
None listed